ArticleAmerican journal of cancer research2020
TFRC promotes epithelial ovarian cancer cell proliferation and metastasis via up-regulation of AXIN2 expression.
Article in American journal of cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- Immunogenic Cell Death-relevant Molecular Patterns, Prognostic Genes, and Implications for Immunotherapy in Ovarian Cancer.Current medicinal chemistry · 2026Article
- Proteomics discovery of MTDH and SND1 interaction vulnerabilities in ovarian cancer.Scientific reports · 2025Article
- Covalent Inhibition of the Peptidyl-Prolyl Isomerase Pin1 by Sulfopin Results in a Broad Impact on the Phosphoproteome of Human Osteosarcoma U2-OS Cells.Proteomics · 2025Article
- Spatially resolved proteomics surveys the chemo-refractory proteins related to high-grade serous ovarian cancer.Clinical and translational medicine · 2025Article
- Article
- Recent progress of ferroptosis in cancers and drug discovery.Asian journal of pharmaceutical sciences · 2024Review
- circ-TFRC downregulation suppresses ovarian cancer progression via miR-615-3p/IGF2 axis regulation.Cancer cell international · 2024Article
- TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.European journal of medical research · 2024Article
- Lactate dehydrogenase A is a diagnostic biomarker associated with immune infiltration, m6A modification and ferroptosis in endometrial cancer.Frontiers in oncology · 2024Article
- Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway.Cancer cell international · 2023Article
- Targeting EFNA1 suppresses tumor progression via the cMYC-modulated cell cycle and autophagy in esophageal squamous cell carcinoma.Discover oncology · 2023Article
- NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma.Cancer gene therapy · 2023Article
- Construction of noninvasive prognostic model of bladder cancer patients based on urine proteomics and screening of natural compounds.Journal of cancer research and clinical oncology · 2023Article
- Overexpressed transferrin receptor implied poor prognosis and relapse in gastrointestinal stromal tumors.Frontiers in oncology · 2023Article
- A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma.Bioscience reports · 2022Article
- Prognostic Ability of Enhancer RNAs in Metastasis of Non-Small Cell Lung Cancer.Molecules (Basel, Switzerland) · 2022Article
- Iron metabolism protein transferrin receptor 1 involves in cervical cancer progression by affecting gene expression and alternative splicing in HeLa cells.Genes & genomics · 2022Article
- Iron contributes to photoreceptor degeneration and Müller glia proliferation in the zebrafish light-treated retina.Experimental eye research · 2022Article
- Single-cell transcriptomics uncover the key ferroptosis regulators contribute to cancer progression in head and neck squamous cell carcinoma.Frontiers in molecular biosciences · 2022Article
- Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer.Journal of big data · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer (EOC) is the most common cause of gynecological cancer death. Recent studies have reported that iron overload could accelerate cancer progression. TFRC is an important participant in intracellular iron transport, and we noticed that it was abnormally overexpressed in EOC; however, its specific role in EOC remained unclear. Therefore, our study aimed to reveal the clinical significance and biological function of TFRC in human EOC. First, we detected dramatically increased TFRC expression in EOC tissues, which was associated with a worse prognosis for patients. Subsequently, we verified that TFRC knockdown significantly inhibited the proliferation and metastasis of EOC cells (SKOV3 and A2780)
Indexed as
Identifiers
32064157PMC7017730W3009702664What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.